Amorphous solid dispersions can improve the oral delivery potential of poorly water-soluble drugs by stabilising the drug in a high-energy amorphous state. Their performance depends on drug–polymer miscibility, thermal mobility, and the ability to generate and maintain supersaturation during dissolution. Formulation screening remains strongly empirical, and individual measurements such as a single glass transition temperature or visual evidence of miscibility rarely provide a complete performance forecast. This limits rational formulation design because stability, dissolution, and precipitation are often interpreted separately. This manuscript describes a conceptual predictive model for estimating amorphous solid dispersion performance from miscibility, glass transition, and dissolution descriptors. The intended outputs are crystallization stability, supersaturation behaviour, and dissolution profile quality. A gradient-boosted regression framework is proposed using formulation-level inputs such as interaction parameters, measured or predicted glass transition temperature, drug loading, polymer characteristics, and early dissolution metrics. The model is intended as a decision-support tool rather than a replacement for experimental confirmation. Conceptually, the model could predict whether an amorphous solid dispersion would be expected to remain physically stable and whether it should maintain a useful supersaturation profile. It could also identify formulation variables most responsible for predicted failure or success. A predictive modelling workflow of this type could reduce the experimental burden of amorphous solid dispersion development by prioritising a smaller set of rational formulation candidates. The approach supports earlier, more integrated decision-making in amorphous formulation design.